Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. (2016)
Attributed to:
Immunity in the face of diversity and the development of novel potent HCV vaccines
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2016.02.007
PubMed Identifier: 26867489
Publication URI: http://europepmc.org/abstract/MED/26867489
Type: Journal Article/Review
Volume: 65
Parent Publication: Journal of hepatology
Issue: 1
ISSN: 0168-8278